| Project/Area Number |
19K17825
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 54010:Hematology and medical oncology-related
|
|---|
| Research Institution | Kanazawa University |
|---|
Principal Investigator |
Iwaki Noriko 金沢大学, 医学系, 助教 (10825706)
|
|---|
| Project Period (FY) |
2019-04-01 – 2021-03-31
|
| Project Status |
Completed (Fiscal Year 2020)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2020: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2019: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | EBV関連リンパ増殖性疾患 / KIR遺伝子プロフィル / EBウイルス関連リンパ増殖性疾患 / EBV特異的CTL |
|---|
| Outline of Research at the Start |
同種造血幹細胞移植後の患者、抗胸腺細胞グロブリン・cyclosporine併用療法等の免疫抑制療法を受けた患者で、Epstein-Barr ウイルス関連リンパ増殖性疾患（ EB virus-associated lymphoproliferative disorder ：EBV-LPD） の発症と患者のkiller cell munoglobulin-like receptor (KIR)遺伝子レパトアとの関連について検討する。
また、KIRプロフィルとEBVウイルス再活性化、EBV-LPD発症との関係を、EBV-DNA量・EBV特異的細胞傷害性T細胞の定期的モニタリングにより明らかにする。
|
| Outline of Final Research Achievements |
To identify the association between KIR gene polymorphisms and susceptibility to EBV-LPD (EB virus-associated lymphoproliferative disorder), we determined EBV copy numbers in the whole blood of patients suspected of having EBV-LPD using quantitative real-time PCR, and determined the KIR gene profile of these patients as well as those who develop non-EBV associated lymphoma and healthy individuals using PCR with specific primers. In patients with EBV-LPD, the frequencies of KIR2DS1, 2DS5 and 2DL5 were significantly lower than those in healthy individuals and non-EBV associated lymphoma. The result suggests that the KIR gene repertoire may be associated with susceptibility to EBV-LPD.
|
| Academic Significance and Societal Importance of the Research Achievements |
KIR 遺伝子プロフィルがEBV-LPDの発症に影響する可能性が示唆されたことで、免疫抑制療法中の患者において、よりEBV-LPDを発症しやすい患者群の特定につながる可能性がある。また、EBV再活性を来した患者において、治療方針の改善につながる可能性がある。
|
